Centre Eugène Marquis

Research site

France Avenue de la Bataille de Flandres Dunkerque, 35000 Rennes, France

3 trials recruiting
Breast cancer · Breast cancer metastatic · Gastroenteropancreatic neuroendocrine tumour disease
Adults and children

About Specializations

Centre Eugène Marquis in Rennes, France specialises in clinical trials of conditions such as Breast cancer, Breast cancer metastatic, Gastroenteropancreatic neuroendocrine tumour disease, Neuroblastoma, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology

The medical center is at the forefront of oncology research, particularly in the treatment of high-risk neuroblastoma. This complex and aggressive cancer primarily affects children, and the center is dedicated to improving outcomes through innovative treatment strategies.

Induction Regimens
High-Dose Chemotherapy
Radiotherapy Techniques
Chemoimmunotherapy

By comparing different therapeutic approaches, the center aims to enhance the event-free survival (EFS) rates for patients, offering hope for improved long-term outcomes.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Avenue de la Bataille de Flandres Dunkerque35000 RennesFrance

Open in maps ↗

Recruiting now: 3 trials
Conditions studied: 7

More sites in Rennes France

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

6 clinical trials

Tumour of ampulla of Vater

Recruiting

Study Comparing mFOLFIRINOX and Capecitabine or Gemcitabine for Patients with Resected Ampullary Adenocarcinoma

Registered drugNo placebo

Study Comparing mFOLFIRINOX and Capecitabine or Gemcitabine for Patients with Resected Ampullary Adenocarcinoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Centre Hospitalier Universitaire De Dijon

Contact Research Centre

Rhabdomyosarcoma

Recruiting

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:The University Of Birmingham

Contact Research Centre

Neuroblastoma

Recruiting

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Busulfan
Sponsor:Institut Gustave Roussy

Contact Research Centre

Ovarian cancer

Not yet recruiting

Phase I/II Study of ubamatamab plus drug combination in patients with ovarian cancer who have poor response to first‑line chemotherapy

Registered drugNo placebo

Phase I/II Study of ubamatamab plus drug combination in patients with ovarian cancer who have poor response to first‑line chemotherapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Arcagy Gineco

Contact Research Centre

Gastroenteropancreatic neuroendocrine tumour disease

Not yet recruiting

68Ga-DOTATATE PET/CT Prognostic Assessment in Patients with Well-Differentiated Grade 2 Gastroenteropancreatic Neuroendocrine Tumors Treated with 177Lu-oxodotreotide and Edotreotide

Registered drugNo placebo

68Ga-DOTATATE PET/CT Prognostic Assessment in Patients with Well-Differentiated Grade 2 Gastroenteropancreatic Neuroendocrine Tumors Treated with 177Lu-oxodotreotide and Edotreotide

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Edotreotide
Sponsor:Centre De Lutte Contre Le Cancer Eugene Marquis

Contact Research Centre

Breast cancer+1

Not recruiting

Study of PF-07220060 and Letrozole for Adults with HR-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drugNo placebo

Study of PF-07220060 and Letrozole for Adults with HR-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Abemaciclib
Sponsor:Pfizer Inc.

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites